# NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

# Health Technology Appraisal

## Bevacizumab and cetuximab for the treatment of advanced colorectal cancer

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Roche Products Ltd (bevacizumab)	Board of Community Health Councils in
Merck Pharmaceuticals (cetuximab)	Wales
	British National Formulary
Patient/carer groups	National Public Health Service for
Beating Bowel Cancer	Wales
Cancer Voices	NHS Confederation
CancerBACUP	NHS Purchasing and Supplies Agency
Colon Cancer Concern	NHS Quality Improvement Scotland
<ul> <li>CORE (Digestive Disorders</li> </ul>	
Foundation)	Comparator manufacturers
Long-term Medical Conditions	Sanofi-Aventis (oxaliplatin)
Alliance	Pfizer Ltd (irinotecan)
Lynn's Bowel Cancer Campaign	Roche Products Ltd (capecitabine)
Macmillan Cancer Relief	Bristol-Myers Squibb Pharmaceuticals
Marie Curie Cancer Care	Ltd (tegafur uracil)
National Cancer Alliance	Mayne Pharma plc (fluorouracil)
National Council for Palliative Care	Medac UK (fluorouracil)
Teenage Cancer Trust	Wyeth Pharmaceuticals Ltd (calcium
Tenovus Cancer Information Centre	levofolinate)
Professional groups	Relevant research groups
Association of Cancer Physicians	<ul> <li>Institute of Cancer Research</li> </ul>
Association of Coloproctologists of	<ul> <li>MRC Clinical Trials Unit</li> </ul>
Great Britain	National Cancer Research Institute
<ul> <li>British Oncological Association</li> </ul>	
<ul> <li>British Oncology Pharmacy</li> </ul>	Assessment team
Association (BOPA)	National Coordinating Centre for Health
<ul> <li>British Psychosocial Oncology</li> </ul>	Technology Assessment
Society (BPOS)	School of Health & Related Research
Cancer Research UK	Sheffield
Royal College of General	Acceptiated Guideline Craupa
Practitioners	<ul> <li>Associated Guideline Groups</li> <li>National Collaborating Centre for</li> </ul>
Royal College of Nursing	Cancer
Royal College of Pathologists	Cancer
Royal College of Physicians' Medical	

Oncology Joint Special	Committee
------------------------	-----------

- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society

#### **Others**

- Department of Health
- East Hampshire PCT
- East Leeds PCT
- Welsh Assembly Government

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

## **Definitions:**

### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, the *British National Formulary*, and the British Medical Association.

#### Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).